COST-EFFECTIVENESS OF PARITAPREVIR/ROTANAVIR/OMBITASVIR WITH OR WITHOUT DASABUVIR IN IRELAND

Author(s)

Baj R¹, Kavanagh J¹, Egan KM², McKinley C¹
¹AbbVie Ltd., Dublin 24, Ireland, ²AbbVie Ltd., Dublin, Ireland

Presentation Documents

PGI19--strong-u-baj-r-u-sup-1-sup-strong-kavanagh-j-sup-1-sup-egan-km-sup-2-sup-mckinley-c-sup-1-sup-br-sup-1-sup-abbvie-ltd-dublin-24-ireland-sup-2-sup-abbvie-ltd-dublin-ireland

OBJECTIVES: Background

Conference/Value in Health Info

2016-10, ISPOR Europe 2016, Vienna, Austria

Value in Health, Vol. 19, No. 7 (November 2016)

Code

PGI19

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Gastrointestinal Disorders

Explore Related HEOR by Topic

Economic Evaluation

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now